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Summary:
Flosequinan (BTS 49465, 7-fluoro-1-methyl-3-methyl- 
sulphinyl-4-quinolone), a recently developed direct- 
acting vasodilator that should cause relatively less re­
flex tachycardia, was given in a single oral dose of 
200 mg to 10 untreated patients with moderate to severe 
hypertension. Flosequinan caused a fall in blood pres­
sure (BP) from 181/116 ±7 /4  to 161/102 ± 5/4 mm Hg 
(P < 0.05). The proportional decrease of mean arterial 
pressure (MAP) was 14.6% (P < 0,01). Together with the 
decrease of BP an increase of heart rate from 79 ± 5 to 
96 ± 5 beats/min occurred (31 ± 4%, P<  0.01). Forearm 
blood flow increased insignificantly (NS) from 3*7 ± 0.6 
to 5.5 ± 1.5 ml/100 ml/min together with a small de­
crease in forearm vascular resistance from 47 ± 7 to 
39 ± 7 arbitrary units (NS). Forearm venous distensibil- 
ity remained stable around 0.03% mmHg (NS). Neuro-
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Introduction
In most patients with hypertension there is an in­
creased total peripheral vascular resistance. A logi­
cal approach in the treatment of hypertension, 
therefore, is the reduction of the elevated resistance 
by means of vasodilating agents.1 The so called 
direct-acting vasodilators such as hydralazine, 
cause a relaxation of the vascular smooth muscles, 
especially in the pre-capillary resistance vessels 
and they have minimal effect on veins.2 The direct 
vasodilation stimulates counter-regulatory mechan­
isms such as activation of the sympathetic system 
(reflex tachycardia), activation of the renin- 
angiotensin-aldosterone system and sodium reten­
tion by the kidney.
Flosequinan (BTS 49456, 7-fluoro~l-methyl-3- 
methylsulphinyl-4-quinolone) is a newly developed 
direct-acting vasodilator. Its hypotensive effect has 
been demostrated in a number of animal models.3
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hormonal parameters showed the consequences of sys­
temic vasodilation: noradrenaline rose from 1.25 ± 0.10 
to 2.88 ± 0.34 nmol/l (P< 0.01), adrenaline from 0.16 ±  
0.03 to 0.35 ± 0.10 nmoi/l (NS), plasma renin activity 
from 2.33 ±0.46 to 3.27 ± 0.73 ng/ml/h (P<0.05) and 
aldosterone from 14.31 ± 2.47 to 26.3 ± 8.02 ng/ml 
(P < 0.05). The serum concentrations of flosequinan 
and its major metabolite were within the therapeutic 
limits. Nine patients experienced minor slde-effects 
such as headache, nausea and palpitations.
We conclude that flosequinan has hypotensive effi­
cacy with signs of systemic counter-regulatory mechan­
isms but without a clear forearm vasodilation. Particu­
larly the venous dilation, claimed in normotensives, 
could not be established in hypertensives.
hypertension
Figure 1 gives the chemical structure. After oral 
intake flosequinan is rapidly absorbed reaching 
peak plasma concentrations after 0.5-1.5 h. It is 
eliminated by oxidation in the liver with a half-life 
of 1.6 h. In contrast, the major and active sulphon 
metabolite, BTS 53554, reaches peak plasma con­
centrations after 6 h with a slow clearance (half-life 
of 37.6 h). This suggests the advantage that the drug 
may be effective when administered once daily.4
A previous study suggests that this drug should 
cause less reflex tachycardia compared with for 
example hydralazine.5 This was thought to result 
from a tendency to a simultaneous dilating activity 
on the venous system, decreasing the venous return 
which offsets the compensatory rise in cardiac out­
put, potentially leading to complaints from the pa­
tients. Previously these venous effects were studied 
in vitro with human tissue6 or in vivo with normo- 
tensive volunteers5 and appeared to be marginal in 
these subjects. Therefore, the present study was 
undertaken to determine the acute haemodynamic 
and humoral effects of ingestion of 200 mg flosequi­
nan in 10 patients with moderate to severe hyper­
tension who were withdrawn from previous treat­
ment at least 1 week before the start of the study.
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Figure 1 Chemical structure of flosequinan (BTS 49465, 7-fluoro
l-methyl-3-methylsulphinyl-4-quinolone)
Patients and methods
Ten patients with a mean DBF of > 105 mmHg 
during at least three control visits at the outpatient 
department were selected. They gave their written 
informed consent for participation in this study. 
The study was approved by the local ethics commit­
tee. Table 1 lists some of the clinical characteristics 
of the patients. Six patients had electrocardio­
graphic and/or echocardiographic evidence of left 
ventricular hypertrophy. Grade 1 to 2 hypertensive 
retinopathy was found at fundoscopy in all patients 
except three. No patient had significant macro­
albuminuria. Seven patients had been treated with 
various anti-hypertensive agents until 1 week before 
the study. Subsequently two patients (nos 6 and 9) 
were found to have a renal artery stenosis. The 
dietary sodium was not restricted.
All patients were studied in the same quiet room 
after an overnight fast. BP was continuously 
recorded non-invasively by means of an Arterio- 
sonde 1225 blood pressure device (Roche Medical 
Electronics Division, Hoffmann-La Roche Oranje- 
burg, NY) and heart rate was calculated from an 
electrocardiographic registration. After 30 min rest, 
supine BP and heart rate were measured every 5 
min before and every 10 min until 6 h after the oral 
ingestion of 200 mg flosequinan. Because we did 
not know the precise effect of the drug the first 
patient (no 1) received only 100 mg. Two hours
after ingestion of the drug all patients were allowed 
to eat a small breakfast in semi-sitting position.
Mean arterial pressure (MAP) was calculated ac­
cording to the formula: MAP = diastolic BP + l/3 of 
the pulse pressure. Forearm blood flow (FBF) was 
measured (mean of at least three FBF readings at 
every time point) before and every 30 min after 
ingestion of flosequinan until 2 h, thereafter every 
hour, by using venous occlusion plethysmography 
with mercury in rubber strain gauges. Forearm vas­
cular resistance (FVR) was calculated from the for­
mula: FVR = MAP/FBF and expressed in arbitrary 
units (AU), Using the same plethysmographic 
method venous distensibility was measured7 ac­
cording to a similar time schedule. Briefly: venous 
congestion at three different inflation pressure 
values of the upper arm BP cuff (usually about 20, 
30 and 40 mmHg) yielded corresponding forearm 
volume changes; the percentage of volume change 
was plotted against cuff pressure. Linear relation 
was assumed and venous distensibility expressed as 
% mmHg-1. Before and after ingestion of flosequi­
nan at 0.5, 1, 1.5, 2, 3, 4, 5 and 6h venous blood 
was drawn from an indwelling cannula, inserted at 
the start of the study, for determination of noradren­
aline (NA), adrenaline, plasma renin activity (PRA), 
aldosterone and flosequinan and its metabolite BTS 
53554. Methods used for the determination of cate­
cholamines by radio-enzymatic assay and PRA and 
aldosterone by radioimmuno assay have all been 
published previously.8“10 Levels of flosequinan and 
its metabolite were measured by HPLC with UV 
detection, at the laboratories of the Boots Company, 
Nottingham (UK). Before and some days after the 
test, blood was drawn for determination of haemo­
globin, leucocytes, thrombocytes, prothrombine 
time, activated partial thromboplastine time, and 
biochemistry including electrolytes, urea, creati­
nine, total protein, albumin, alkaline phosphatase, 
transaminases and gamma glutamyl transferase.
Statistical analysis
The Student ¿-test for paired observations was used. 
Differences were considered to be significant at P
Table 1 Clinical characteristics of the patients
Patient no. Sex Age (years} QI (kg/m*} BP aten try 
(mm Hg)
Serum creatinine (mmol/1) Type of hypertension
1 F 44 33.2 159/109 77 Essential
2 F 35 23.4 153/108 62 Essential
3 M 58 29.8 190/130 96 Essential
4 M 43 32.8 145/97 83 Essential
5 M 51 24.9 163/120 97 Essential
6 F 45 38.8 204/100 75 URAS
7 F 48 35.0 204/134 71 Essential
8 F 49 39.1 199/124 74 Essential
9 F 30 21.3 189/137 58 URAS
10 F 52 27.9 183/106 70 Essential
Mean 46 30.7 195/119 76
Range 30-58 21.3—39.1 174-220
109-130
58-79
QI: Quetelet index; URAS: unilateral renal artery stenosis
values of ^  0.05. Two-sided results are presented as 
mean ± s.e. unless indicated otherwise.
Results
Table 1 summarises some patient characteristics 
and the automatically measured baseline BPs. As 
known, the arteriosonde BPs are nearly always 
6-8 mmHg lower than the sphygmomanometer 
readings and indeed two patients (nos 4 and 6) 
appeared to have DBP of < 105 mmHg despite out­
patient DBP of >105 mmHg. Besides by the 
method, the difference can also partly be ascribed to 
the level of the arm above the heart and to the quiet 
room with constant temperature.
Although the 100 mg dose of flosequinan in 
patient no 1 resulted in a smaller decrease of 
MAP (9 mmHg) compared with the mean effect of 
the 200 mg dose in the other nine patients 
(23 mmHg ± 4 mmHg), the results of all 10 patients 
are presented together.
Figure 2 shows the course of the BP, MAP and 
heart rate throughout the test period. After ingestion 
of flosequinan, BP gradually decreased from an 
average of 181 ± 7/116 ±4 to 161 ± 5/102 ± 4 
mmHg after 2h (P< 0.025 except at 30 min) and 
remained approximately constant thereafter. MAP 
fell from 137 ± 5 to 117 ± 2 mmHg (P  < 0.01 at all 
times except at 360 min, P <  0.05) with a percent­
age fall of 14.6. In individual patients the maximal 
MAP reduction ranged from 3.5 to 27.1%, mean
15.8 ± 2.8%. The two patients with renal artery 
stenosis showed a maximal MAP response of
20.8 ± 1.9 mmHg compared with 14.6 ± 2.9 mmHg 
in the remaining eight patients. Together with BP 
reduction heart rate rose from 79 ± 5 to 96 ± 5 
beats/min (31 ±  4%, P < 0.01 at all times except at 
30 min, P  < 0.05) and started to return to baseline 
at 5 h.
The FBF increased insignificantly (NS) and only 
transiently from 3.7 ± 0.6 to 5.5 ± 1.5 ml/100 ml/
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Figure 2 Course of BP and heart rate before and after ingestion of 
flosequinan in the 10 hypertensive patients, Systolic, diastolic 
and mean arterial blood pressure (black dots in the columns) are 
given as mean ± s.e. BP significantly lower (P < 0.025) than 
baseline at all times except at 30 min. Heart rate changes are 
significant (P <  0,01) at all times except at 30 min (P < 0.05)
min during the first hour, together with a small 
decrease in FVR from 47 ± 7 to 39 ± 7 AU (NS). No 
change, especially no increase of the venous disten­
sibility could be detected: it remained stable around 
0.03% mmHg"1 (NS) (Figure 3).
Figure 4 shows the humoral compensatory reac­
tions to the systemic hypotensive effect of the 
vasodilator. Plasma NA level rose from 1.25 ± 
0.10 to a maximum of 2.88 ± 0.34 nmol/1 (P < 0.01), 
adrenaline rose gradually from 0.16 ± 0.03 to 
0.35 ± 0*10 nmol/1 (NS), PRA rose from 2.33 ± 0.46 
to 3.27 ± 0.73 ng/ml/h (P < 0.05). Aldosterone 
rose from 14.31 ± 2.47 to 26.30 ± 8.02 ng/100 ml 
[P < 0.05),
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Figure 3 Course of mean arterial pressure (MAP), forearm blood flow (FBF), forearm vascular resistance (FVR) and venous distensibil- 
ity (VD) after ingestion of flosequinan in the 10 patients with moderate to severe hypertension. Mean ± s.e. are presented. MAP:
P < 0.01 at all times except at 360 min (P < 0.05); FBF, FVR, VD: NS. Note: the x axis does not start at 0
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Figure 4 Effects of flosequinan on noradrenaline (NA), adrenaline, plasma renin activity (PRA) and aldosterone in the 10 patients, 
Mean ± s.e. are presented. NA: P < 0.01; adrenaline: NS; PRA: P < 0.02; aldosterone:? < 0.05. Note; the x axis does not start at 0
Figure 5 shows the serum levels of flosequinan 
(BTS 49465) and its major metabolite (BTS 53554) 
at different time points. Flosequinan reached its 
peak plasma concentration in 1 h after oral intake; 
the metabolite levels gradually increased and 
seemed to reach a maximum at 6 h. The concentra­
tion of flosequinan and its metabolite together 
reached a peak at 3 h and then started to fall slowly.
Adverse events like headache, palpitations, 
nausea, vomiting and eructation were mentioned 
(Table 2). One patient experienced a vagal reaction: 
he became pale and complained of nausea and
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Figure 5 Serum levels of flosequinan (O) and its major metabo­
lite (BTS 53554; {•)) at 30, 60, 90, 120, 180, 240, 300 and 360 
min after oral ingestion of 200 mg flosequinan in the 10 patients. 
Mean ± s.e. are presented
Table 2 Spontaneously reported side-effects
Side-effects No. of patients
Compensatory reactions
Headache 7
Palpitations 2
Abdominal discomfort
Nausea 5
Vomiting 2
Eructation 1
Vagal reaction 1
giddyness. BP (lowest value 121/80 mmHg) and 
heart rate (from 93 to 63 beats/min) decreased. Head 
down tilting and voluntary leg exercise for a few 
minutes induced a complete recovery.
No haematological or biochemical derangements 
were noted.
Discussion
The present study demonstrates that flosequinan 
given as an oral dose of 200 mg to patients with 
moderate to severe hypertension effectively lowers 
BP with signs of systemic counter-regulatory 
mechanisms, but without a clear forearm vasodila­
tion, Particularly, the claimed trend towards venous 
dilation found in normotensives5 could not be 
established in our hypertensive patients.
It has been proven in other studies that flosequi­
nan is a vasodilator, acting directly on vascular 
smooth muscle, probably by modifying the availa­
bility of intracellular free ionised calcium.11,12 The 
systemic vasodilatory capacity is supported by the 
occurrence of increases in heart rate, found in this 
study and in other reports,4,1344 and by the changes 
in the respective neurohormonal parameters.
In contrast to the study of Cowley et a l ,5 we were 
not able to demonstrate a clear and consistent 
arteriolar and venous dilation in the forearm. This 
discrepancy can be explained by a number of differ­
ences between the two studies. Firstly, we studied 
moderate to severe hypertensives with more ad­
vanced atherosclerosis whereas Cowley et al stud­
ied six normotensives. It might be possible that the 
blunted vasodilatory response in terms of FBF and 
venous distensibility in hypertensive patients is 
due to reduced baroreflex sensitivity. Other poss­
ible differences between the two studies may be the 
mean age, mean body mass index and mean dose 
(400 vs. 200 mg).
Some authors claim that because of the effect on 
both arteries and veins flosequinan has the advan­
tage of a relatively small rise in heart rate.5,15 In our
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study at the time point of the maximal hypotensive 
effect (MAP — 14.6%), the heart rate increased by 
31.4%. This is similar or even more pronounced 
than the results of some previous workers13,14 and 
represents a normal physiological response to sys­
temic vasodilation which partly attenuates the re­
duction in BP by the drug. In comparison with our 
own previous studies, flosequinan results in a simi­
lar increase in heart rate when compared with 
monotherapy with nifedipine,16 endralazine,17 diaz- 
oxide18 and pinacidil.19 On the other hand, when 
flosequinan, like other vasodilators, is administered 
in a chronic regimen together with beta-adreno- 
ceptor blocking agents and diuretics, there is hardly 
any change in heart rate.4,14 Furthermore, the hypo­
tensive activity of flosequinan at the time point of 
the maximal heart rate increase was not stronger 
than the effects of other vasodilators, previously 
studied by us in similar protocols in other patients.
In contrast to previous clinical trials in which 
flosequinan reduced BP in hypertensive patients 
without changing renal blood flow, glomerular fil­
tration rate or PRA, aldosterone and NA,15,20,21 we 
detected significant increases. It has to be empha­
sised that Dupont et al performed a chronic study 
with a dose of 100 mg and that Cowley et al used 
flosequinan as a third agent next to a diuretic and a 
beta-blocker.
Our observation was too short to measure sodium 
retention, another important effect of vasodilators, 
possibly leading to subjective side-effects.1
Serum levels of flosequinan and its metabolite 
were measured to see if they were comparable with 
the levels obtained in other studies. The values in 
the present study were within the expected limits.4
With this single dose of 200 mg, nine of 10 pa­
tients experienced side-effects: compensatory re­
actions such as headache and palpitations, and ab­
dominal discomfort such as nausea and vomiting. 
Another study reported also that the frequency of 
reported adverse events is statistically larger than 
with placebo.12
Our study has some weaknesses. Firstly it was 
uncontrolled, although most parameters were 
measured objectively. The FBF and venous disten­
sibility values were calculated from the curves by a 
blinded observer, Secondly, the results of a single 
dose study can not be extrapolated to the chronic 
use of the drug. Once steady-state levels of the drug 
have been reached results may be different and 
counter-regulatory reactions may be less prominent. 
Thirdly our study includes only a small number of 
patients.
In recent studies flosequinan is used effectively 
in patients with severe heart failure.22-28 Despite 
encouraging symptomatic improvement the com­
pany withdrew the drug from the market because 
preliminary results showed that in patients with 
heart failure the use of 100 mg caused an increased 
mortality, 75 mg caused an increase in hospital ad­
missions and that the efficacy of 50 mg had not 
been proven,29 The consequences from these find­
ings in heart failure to hypertension are limited 
because of differences in pathophysiology, co­
morbidity and comedication. However, the effect of 
compounds similar to flosequinan that may be
developed in the future should be studied both in 
hypertension as well as in heart failure.
Conclusions
We conclude that flosequinan after oral ingestion of 
200 mg has a hypotensive effect via systemic vaso­
dilation although we could not demonstrate this 
vasodilation in the forearm of hypertensive pa­
tients, either on the arterial, or on the venous side. 
Up to now flosequinan, as hypotensive drug, has no 
major advantages compared with other well-known 
direct-acting vasodilators. The drug exhibits the ex­
pected side-effects when given as monotherapy in a 
single dose of 200 mg.
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